Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — 18th German Corporate Conference GCC 2019

40 slides from Fresenius SE & Co. KGaA's conference presentation, Jan 22, 2019

  1. Slide 1: 18th German Corporate Conference GCC

    18th German Corporate Conference GCC Frankfurt, 21-22 January 2019 Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: A Global Leader In HealthCare Products And Services

    A Global Leader In HealthCare Products And Services ~€33.9 bn in Sales Global presence in (as of Dec. 31, 2017) 100+ countries Total Shareholder Return: 10-year CAGR: ~15% Strong portfolio 277,000+ employees of products (30% of sales) worldwide and services (70% of sales) (as of September 30, 2018)

  4. Slide 4: Strong and Balanced Health Care Portfolio

    Strong and Balanced Health Care Portfolio Ownership: ~31% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis Products Hospital Supplies Hospital Operation Projects and Services for Health Care Services Hospitals • Dialysis services • IV drugs • Acute care • Post-acute care • Hemodialysis produc

  5. Slide 5: Total Shareholder Return – CAGR, Rounded

    Total Shareholder Return – CAGR, Rounded 10 years 15 years 20 years 15% 14% 13% 12% 10% 9% 8% 8% 7% 6% 6% 4% DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 MSCI World Fresenius Fresenius Health Care Health Care Health Care Source: Bloomberg; dividen

  6. Slide 6: Fresenius Group Consistent Cash Generation

    Fresenius Group Consistent Cash Generation CFFO margin FCF margin (before acquisitions & dividends) % % 14 10 13 12.6 12.2 7.4 7.6 12.0 12.0 8 12 11.4 11.4 11.6 6.7 6.7 6.6 6.3 6.2 11.0 10.3 10.9 5.6 5.6 11 6 5.2 10 8.7 4 2.7 9 8 2 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2007 2008 200

  7. Slide 7: Fresenius Medical Care: Global Dialysis Market Leader

    Fresenius Medical Care: Global Dialysis Market Leader • The world’s leading provider of dialysis products Market Dynamics and services treating more than 329,000 patients1 in ~3,800 clinics1 Global Dialysis Market 2017: • Provide highest standard of product quality and • ~€70 bn • ~6% patient growth

  8. Slide 8: Fresenius Kabi: A Leading Global Hospital Supplier

    Fresenius Kabi: A Leading Global Hospital Supplier • Comprehensive product portfolio for critically and Market Dynamics chronically ill patients • Strong Emerging Markets presence Global Addressable Market 2017: • Leading market positions in four product • ~€81 bn segments Growth Drivers: • Patent e

  9. Slide 9: Fresenius Helios: Europe's Largest Private Hospital Operator – Helios Germany

    Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Germany • ~6%1 share in German acute care hospital Market Dynamics market • Organic growth based on growing number of German Acute Care Hospital Market: admissions and reimbursement rate increases • ~€98 bn2 • Ranks as quality leade

  10. Slide 10: Fresenius Helios: Europe's Largest Private Hospital Operator – Helios Spain

    Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Spain • ~€2.6bn1 sales in 2017 Market Dynamics • ~11% share in Spanish private hospital market Spanish Private Hospital Market: • Market leader in size and quality with excellent • ~€14 bn2 growth prospects Growth Drivers: • Broad r

  11. Slide 11: Fresenius Vamed: Leading Global Hospital Projects and Services Specialist

    Fresenius Vamed: Leading Global Hospital Projects and Services Specialist • Manages hospital construction/expansion Market Dynamics projects and provides services for health care facilities worldwide Growth Drivers: • Offers project development, planning, turnkey • Emerging Market demand for buildin

  12. Slide 12: Fresenius Group: 2018 Financial Outlook by Business Segment

    Fresenius Group: 2018 Financial Outlook by Business Segment €m FY/17 Q1-3/18 FY/18e1 (except otherwise stated) Base Actual FY/18e1 New Sales growth (org) 6,358 7% 4% - 7% (top-end) EBIT growth (cc) 1,1772 1%6 -2% to 1%2 1% - 3%2 EBIT growth (cc) excl. biosimilars 1,2373 11%6 ~6% - 9%3 ~9% - 11%3 Sal

  13. Slide 13: Fresenius Group: 2018 Financial Guidance

    Fresenius Group: 2018 Financial Guidance €m FY/17 Q1-3/18 (except otherwise stated) Base Actual FY/18e1 FY/18e1 Sales growth (cc) 32,8422 5% 5% - 8% (low-end) Net income3 1,8044 7% 6% - 9%5 (low-end) growth (cc) Net income3 growth (cc) 1,8476 12% ~10% - 13%7 (low-end) excl. Biosimilars 1 Excluding e

  14. Slide 14: Basis for guidance

    Basis for guidance Targets FY/18 €m FY/17 (cc) Sales reported 33,886 adjustments from IFRS 15 -486 divestitures of Care Coordination activities at FMC -558 Basis sales guidance 32,842 (low-end) 5-8% Net income reported 1,814 Acquistion-related expenses 43 Book gain from U.S. tax reform -103 FCPA pro

  15. Slide 15: Fresenius Group: Q3/18 Highlights

    Fresenius Group: Q3/18 Highlights ● Delaware Supreme Court upholds Fresenius' termination of merger agreement with Akorn (December 7, 2018) ● Kabi showed an excellent financial performance driven by all regions and product categories ● Decline in admissions and preparatory activities for regulatory

  16. Slide 16: Fresenius Group: Current Topics (1/4)

    Fresenius Group: Current Topics (1/4) Courts ruled in favor of Fresenius in Akorn suit • On October 1, Delaware Chancery Court ruled in favor of Fresenius, affirming the termination of the merger agreement • The court agreed Akorn had violated terms and conditions of the agreement and suffered mater

  17. Slide 17: Fresenius Group: Current Topics (2/4)

    Fresenius Group: Current Topics (2/4) Kabi growth initiatives IV drugs market in North America • Production in new compounding center in • Continue to see low single-digit price Massachusetts has begun declines for our base portfolio of injectable generics • New pharmaceutical compounding center ope

  18. Slide 18: Fresenius Group: Current Topics (3/4)

    Fresenius Group: Current Topics (3/4) Helios Germany • Trend towards outpatient treatments was • Helios initiated a comprehensive set of exacerbated by further challenges such measures to master the challenges as: ahead:  Higher than usual level of doctor and  New business units “Ambulatory Patien

  19. Slide 19: Fresenius Group: Current Topics (4/4)

    Fresenius Group: Current Topics (4/4) Helios Spain • New hospital opened in Córdoba Andalusia • Construction of Protontherapy Center on on September 17, 2018 schedule  €50 million investment  €40 million investment  100 large private patient rooms, 24 h  Infrastructure has been built in just 12

  20. Slide 20: Financial Review Q3/18

    Financial Review Q3/18 18th German Corporate Conference GCC 21-22 January 2019 © Fresenius SE & Co. KGaA Investor Relations 20

  21. Slide 21: Fresenius Group: Q3/18 & Q1-3/18 Profit and Loss Statement

    Fresenius Group: Q3/18 & Q1-3/18 Profit and Loss Statement €m Q3/18 Δ YoY cc Q1-3/18 Δ YoY cc Sales 8,192 4%1 24,695 5%1 EBIT 1,112 0% 3,311 -1%/1%2 EBIT (excl. biosimilars) 1,153 2% 3,424 2%/4%2 Net interest -139 13% -436 6% Income taxes -208 23% -632 23% Net income 445 8% 1,367 7% Net income (excl

  22. Slide 22: Fresenius Group: Q3/18 Business Segment Growth

    Fresenius Group: Q3/18 Business Segment Growth Organic sales growth EBIT growth (cc) +3%1 -1%3/4%2 +8% 5%/14%4 +2% -12%/-6%5 +30% +107%/7%5 +4%1 0%3/2%3,4 1 Growth rates adjusted for IFRS 15 adoption and divestitures of Care Coordination activities 2 Excluding gains from divestitures of Care Coordin

  23. Slide 23: Fresenius Kabi: Q3/18 Regional Highlights (1/2)

    Fresenius Kabi: Q3/18 Regional Highlights (1/2) North America • 12% organic sales growth in Q3/18 • 37 Kabi-marketed IV drugs currently designated in shortage (vs. 24 at Q4/17) • Increase FY/18 outlook: Mid-to-high-single-digit organic sales growth (previously: Mid-single- digit) Europe • 1% organic

  24. Slide 24: Fresenius Kabi: Q3/18 Regional Highlights (2/2)

    Fresenius Kabi: Q3/18 Regional Highlights (2/2) Emerging Markets China: 13% organic sales growth Asia-Pacific ex China: 3% organic sales growth impacted by phasing within operating business Latin America/Africa: 13% organic sales growth Total Emerging Markets Confirm FY/18 outlook: Double-digit orga

  25. Slide 25: Fresenius Kabi: Q3 & Q1-3/18 EBIT Growth

    Fresenius Kabi: Q3 & Q1-3/18 EBIT Growth €m Q3/18 Δ YoY cc Q1-3/18 Δ YoY cc North America 236 16% 678 10% Margin 38.1% 110 bps 38.5% 50 bps Europe 84 8% 258 8% Margin 15.6% 70 bps 15.6% 70 bps Asia-Pacific/Latin America/Africa 99 2% 282 11% Margin 20.1% -100 bps 19.6% 10 bps Corporate and Corporate

  26. Slide 26: Fresenius Helios

    Fresenius Helios Helios Germany Helios Spain • Trend towards outpatient treatments was • Excellent sales growth of 6% in Q3/18 exacerbated by further challenges • Additional month of consolidation • Additional “DRG catalogue effects” and contributed significantly to 20% sales preparatory structural

  27. Slide 27: Fresenius Helios: Q3 & Q1-3/18 Key Financials

    Fresenius Helios: Q3 & Q1-3/18 Key Financials €m Q3/18 Δ YoY Q1-3/18 Δ YoY Total sales 2,088 -4%/2%2 6,762 5%/7%2 Thereof Helios Germany 1,410 -7%/0%2 4,531 -1%/2%2 Thereof Helios Spain1 678 6% 2,231 20% Total EBIT 204 -12%/-6%2 775 1%/3%2 Margin 9.8% -90 bps 11.5% -50 bps Thereof Helios Germany 143

  28. Slide 28: Fresenius Vamed

    Fresenius Vamed • Excellent organic sales growth of 30% in €m Q3/18 Δ YoY Q1-3/18 Δ YoY Q3/18 Total sales 476 78% 991 32% • Both, service business and project 34%3 17%3 business contributed to strong growth in Q3/18 Project 161 38% 352 17% business • Transferred post-acute care business  Contribute

  29. Slide 29: Cash Flow

    Fresenius Group: Cash Flow Operating CF Capex (net) Free Cash Flow1 €m Q3/18 LTM Margin Q3/18 LTM Margin Q3/18 LTM Margin 366 18.4% -152 -7.9% 214 10.5% 128 6.2% -94 -4.9% 34 1.3%2 54 2.2% -9 -1.2% 45 1.0% Corporate/Other -8 n.a. -14 n.a. -22 n.a. Excl. FMC 540 11.2%3 -269 -6.1% 271 5.1%3 1,149 10.5

  30. Slide 30: Attachments

    Attachments 18th German Corporate Conference GCC 21-22 January 2019 © Fresenius SE & Co. KGaA Investor Relations 30

  31. Slide 31: Calculation of Noncontrolling Interest

    Fresenius Group: Calculation of Noncontrolling Interest €m Q1-3/18 Q1-3/17 Earnings before tax and noncontrolling interest 2,875 3,038 Taxes -632 -855 Noncontrolling interest, thereof -876 -854 Fresenius Medical Care net income not attributable to -651 -612 Fresenius (Q1-3/18: ~69%) Noncontrolling i

  32. Slide 32: Cash Flow

    Fresenius Group: Cash Flow €m Q3/18 LTM Margin Δ YoY Operating Cash Flow 1,149 10.5% 1% Capex (net) -525 -5.8% -22% Free Cash Flow 624 4.7% -12% (before acquisitions and dividends) Acquisitions (net) -335 Dividends -59 Free Cash Flow 230 5.5% -44% (after acquisitions and dividends) 18th German Corpo

  33. Slide 33: Leverage Ratio

    Fresenius Group: Leverage Ratio 4.0 4,00 Net Debt/EBITDA target 2018 3.44 Comparable level to2 year-end 2017 3.5 3,50 3.22 3 3.0 3,00 2.96 3 3.02 3.00 3.02 2.98 2.97 2.98 2.84 2.80 2.75 2.67 2.65 2.5 2,50 2.59 2.55 2.53 2.33 2,00 1 2008 2009 2010 2011 2012 2013 2014 2015 2016 Q1 Q2 Q3 Q4 Q1 Q2 Q3 20

  34. Slide 34: Kabi: Organic Sales Growth by Regions

    Fresenius Kabi: Organic Sales Growth by Regions Δ YoY Δ YoY €m Q3/18 organic Q1-3/18 organic North America 620 12% 1,760 8% Europe 538 1% 1,658 3% Asia-Pacific/Latin 492 11% 1,439 12% America/Africa Asia-Pacific 337 9% 964 12% Latin America/Africa 155 13% 475 11% Total sales 1,650 8% 4,857 7% 18th G

  35. Slide 35: Kabi: Organic Sales Growth by Product Segment

    Fresenius Kabi: Organic Sales Growth by Product Segment Δ YoY Δ YoY €m Q3/18 organic Q1-3/18 organic IV Drugs 699 8% 2,025 6% Infusion Therapy 228 6% 703 9% Clinical Nutrition 458 12% 1,338 12% Medical Devices/ 265 2% 791 3% Transfusion Technology Total sales 1,650 8% 4,857 7% 18th German Corporate

  36. Slide 36: Helios: Key Measures

    Fresenius Helios: Key Measures Q1-3/18 FY/17 Δ No. of hospitals Germany 87 111 -22% - Acute care hospitals 84 88 -5% No. of hospitals Spain 46 45 2% (Hospitals) No. of beds Germany 29,253 34,610 -15% - Acute care hospitals 28,726 29,438 -2% No. of beds Spain 6,803 6,652 2% (Hospitals) Admissions Ger

  37. Slide 37: Reconciliation Q3/18

    Reconciliation Q3/18 Consolidated results for Q3/18 include special items related to the Akorn transaction. These are mainly transaction costs in the form of legal and consulting fees as well as costs of the financing commitment for the Akorn transaction. Moreover special items arose from gains/loss

  38. Slide 38: Reconciliation Q1-3/18

    Reconciliation Q1-3/18 Consolidated results for Q1-3/18 include special items related to the Akorn transaction. These are mainly transaction costs in the form of legal and consulting fees as well as costs of the financing commitment for the Akorn transaction. Moreover special items arose from gains/

  39. Slide 39: 25th Consecutive Dividend Increase

    Fresenius Group: 25th Consecutive Dividend Increase CAGR 0.75 +16% 0.62 0.55 0.44 € 0.42 0.37 0.32 0.29 0.25 0.22 0.23 0.19 0.16 0.02 '93 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 Dividend growth aligned to EPS growth Pay-out ratio: 23% 18th German Corporate Conference GCC 21-22 January 20

  40. Slide 40: Financial Calendar / Contact

    Financial Calendar / Contact Financial Calendar 20 February 2019 Results FY/18 02 May 2019 Results Q1/19 17 May 2019 Annual General Meeting 30 July 2019 Results Q2/19 29 October 2019 Results Q3/19 Please note that these dates could be subject to change. Contact Investor Relations Fresenius SE & Co.

Fresenius SE & Co. KGaA — 18th German Corporate Conference GCC 2019 on 6ix